Figure 5.

FASN induces gemcitabine chemoresistance in PDAC cells via regulation of PKM2. (A and B) PANC-1 and MIA PaCa-2 cells were transfected with the indicated constructs. Cells were treated with gemcitabine (10 µM) for 24 h prior to harvest. Cells were harvested for (A) western blot analysis and (B) measurement of caspase-3 activity. Data are presented as the mean ± SD from two replicates. (C and D) PANC-1 and MIA PaCa-2 cells were transfected with the indicated constructs. Cells were treated with different doses of gemcitabine for 24 h prior to measurement. Cell viability was measured by MTS Cell Proliferation assay. Data are presented as the mean ± SD from three replicates. *P<0.05. (E) PANC-1 and MIA PaCa-2 cells were transfected with indicated constructs. Cells were treated with or without gemcitabine (10 µM). Equal numbers of cells and control cells were seeded onto 60-mm dishes. After 7 days, the cells were fixed and stained with crystal violet. Data are presented as the mean ± SD from two replicates. *P<0.05. FASN, fatty acid synthase; PDAC, pancreatic ductal adenocarcinoma; PKM2, pyruvate kinase M2; SD, standard deviation; OD, optical density; Myc, V-myc avian myelocytomatosis viral oncogene homolog.